OR WAIT null SECS
April 01, 2024
There are considerations companies may want to consider before seeking out a service provider.
October 05, 2023
POINT is a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.
September 25, 2023
The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.
September 01, 2023
There are many promising trials in the pipeline that may bring big news for major therapeutic areas.
August 21, 2023
The expanded operations will also support the start of proline/alanine/serine (PAS)-nomacopan clinical trials in geographic atrophy (GA).
August 10, 2023
The initial collaboration between the two companies began in 2017 with an extension announced in 2021.
July 27, 2023
The partnership is an extension of the collaboration from AbbVie and Scripps Research that was formed in 2019, according to the press release.
June 08, 2023
The document builds on key concepts outlined in ICH E8(R1) General Considerations for Clinical Studies.
June 02, 2023
Hope is on the horizon as novel solutions and improvements aimed at benefitting the drug development process with the right framework are coming to the fore.
April 28, 2023
clonoSEQ Assay is authorized by FDA for MRD assessment in lymphoid malignancies and is highly accurate, sensitive, and standardized compared to other technologies used for disease burden assessment.